PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.
Saved in:
| Title: | PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer. |
|---|---|
| Authors: | Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sehgal K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Egloff AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Thai TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Monge OA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Center for Cancer Research and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Chuong CL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Center for Cancer Research and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Senent Y; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Center for Cancer Research and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Lineberry MS; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Eschle BK; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Haratani K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ivanova EV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Campisi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA., Quadarella JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gedeon PC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Schoenfeld JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kono M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fahey CG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chayawatto C; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Ngo K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Manguso RT; Broad Institute of MIT and Harvard, Cambridge, MA, USA. rmanguso@broadinstitute.org.; Center for Cancer Research and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. rmanguso@broadinstitute.org., Uppaluri R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ravindra_uppaluri@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. ravindra_uppaluri@dfci.harvard.edu.; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. ravindra_uppaluri@dfci.harvard.edu., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_barbie@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. david_barbie@dfci.harvard.edu.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA. david_barbie@dfci.harvard.edu.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. david_barbie@dfci.harvard.edu.; Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA, USA. david_barbie@dfci.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2026 May 02. Date of Electronic Publication: 2026 May 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
